Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Citi
Daiichi Sankyo
AstraZeneca
QuintilesIMS
US Army

Generated: June 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FAMOTIDINE; IBUPROFEN

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for Famotidine; Ibuprofen

Trial ID Title Status Sponsor Phase Summary
NCT00450216 Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00450658 Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00613106 Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
NCT00984815 Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
NCT01563185 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed Pediatric Rheumatology Collaborative Study Group Phase 4 The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
NCT01563185 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 4 The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
NCT03695172 Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section Not yet recruiting Duke University Phase 4 The purpose of this prospective single center, randomized study is to determine if ultrasound guided Transversus Abdominis Plane (TAP), Quadratus Lumborum (QL), and Erector Spinae Plane (ESP) blocks decrease opioid consumption in subjects undergoing elective cesarean section.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Famotidine; Ibuprofen

Condition Name

Condition Name for Famotidine; Ibuprofen
Intervention Trials
Chronic Low Back Pain 2
Osteoarthritis 2
Chronic Soft Tissue Pain 2
Chronic Regional Pain Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Famotidine; Ibuprofen
Intervention Trials
Nociceptive Pain 2
Low Back Pain 2
Back Pain 2
Arthritis, Rheumatoid 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Famotidine; Ibuprofen

Trials by Country

Trials by Country for Famotidine; Ibuprofen
Location Trials
United States 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Famotidine; Ibuprofen
Location Trials
Texas 2
Pennsylvania 2
Massachusetts 1
Louisiana 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Famotidine; Ibuprofen

Clinical Trial Phase

Clinical Trial Phase for Famotidine; Ibuprofen
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Famotidine; Ibuprofen
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Famotidine; Ibuprofen

Sponsor Name

Sponsor Name for Famotidine; Ibuprofen
Sponsor Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland 5
Duke University 1
Pediatric Rheumatology Collaborative Study Group 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Famotidine; Ibuprofen
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Baxter
Merck
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.